226 related articles for article (PubMed ID: 34253388)
21. Molecular Heterogeneity of Endometrioid Ovarian Carcinoma: An Analysis of 166 Cases Using the Endometrial Cancer Subrogate Molecular Classification.
Leskela S; Romero I; Rosa-Rosa JM; Caniego-Casas T; Cristobal E; Pérez-Mies B; Gutierrez-Pecharroman A; Santón A; Ojeda B; López-Reig R; Palacios-Berraquero ML; Andrada E; Montes S; Pastor F; Gomez MC; López-Guerrero JA; Poveda A; Palacios J
Am J Surg Pathol; 2020 Jul; 44(7):982-990. PubMed ID: 32384322
[TBL] [Abstract][Full Text] [Related]
22. Analysis of the immune checkpoint lymphocyte activation gene-3 (LAG-3) in endometrial cancer: An emerging target for immunotherapy.
Zhang Y; Yang R; Xu C; Zhang Y; Deng M; Wu D; Tang F; Liu X; Han Y; Zhan Y; Miao J
Pathol Res Pract; 2022 Aug; 236():153990. PubMed ID: 35749914
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of prognostic potential of β-catenin and L1CAM expression according to endometrial cancer risk group.
Yoon H; Suh DH; Kim K; No JH; Kim YB; Kim H
Gynecol Oncol; 2024 May; 184():132-138. PubMed ID: 38309030
[TBL] [Abstract][Full Text] [Related]
24. POLE and Mismatch Repair Status, Checkpoint Proteins and Tumor-Infiltrating Lymphocytes in Combination, and Tumor Differentiation: Identify Endometrial Cancers for Immunotherapy.
Dong D; Lei H; Liu D; Bai H; Yang Y; Tang B; Li K; Liu J; Xu G; Xiao X
Front Oncol; 2021; 11():640018. PubMed ID: 33816285
[TBL] [Abstract][Full Text] [Related]
25. Prospective Clinical Prognostication of Endometrial Carcinomas Based on Next-Generation Sequencing and Immunohistochemistry-Real-World Implementation and Results at a Tertiary Care Center.
Davies KD; Smith LP; Guimaraes-Young A; Corr BR; Fisher CM; Guntupalli SR; Berning AA; Post MD; Pino D; Aisner DL; Wolsky RJ
Int J Gynecol Pathol; 2024 Jul; 43(4):335-348. PubMed ID: 37922951
[TBL] [Abstract][Full Text] [Related]
26. "Surface epithelial slackening" pattern in endometrioid carcinoma: A morphological feature for differentiating the POLE mutation-subtype from the no specific molecular profile subtype.
Kitazono I; Akahane T; Yokoyama S; Kobayashi Y; Togami S; Yanazume S; Tasaki T; Noguchi H; Tabata K; Kobayashi H; Tanimoto A
Pathol Res Pract; 2023 Jul; 247():154563. PubMed ID: 37229919
[TBL] [Abstract][Full Text] [Related]
27. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts.
Fremond S; Andani S; Barkey Wolf J; Dijkstra J; Melsbach S; Jobsen JJ; Brinkhuis M; Roothaan S; Jurgenliemk-Schulz I; Lutgens LCHW; Nout RA; van der Steen-Banasik EM; de Boer SM; Powell ME; Singh N; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Smit VTHBM; Creutzberg CL; Horeweg N; Koelzer VH; Bosse T
Lancet Digit Health; 2023 Feb; 5(2):e71-e82. PubMed ID: 36496303
[TBL] [Abstract][Full Text] [Related]
28. Molecular Landscape of Mullerian Clear Cell Carcinomas Identifies The Cancer Genome Atlas-like Prognostic Subgroups.
Irshaid L; Costigan DC; Dong F; Matulonis UA; Nucci MR; Kolin DL
Mod Pathol; 2023 May; 36(5):100123. PubMed ID: 36857998
[TBL] [Abstract][Full Text] [Related]
29. Combination of Proactive Molecular Risk Classifier for Endometrial cancer (ProMisE) with sonographic and demographic characteristics in preoperative prediction of recurrence or progression of endometrial cancer.
Eriksson LSE; Nastic D; Lindqvist PG; Imboden S; Järnbert-Pettersson H; Carlson JW; Epstein E
Ultrasound Obstet Gynecol; 2021 Sep; 58(3):457-468. PubMed ID: 33314410
[TBL] [Abstract][Full Text] [Related]
30. Harmonized molecular classification; assessment of a single-test ProMisE NGS tool.
Jamieson A; McConechy MK; Lum A; Leung S; Thompson EF; Senz J; Talhouk A; Huntsman DG; Bashashati A; Gilks CB; McAlpine JN
Gynecol Oncol; 2023 Aug; 175():45-52. PubMed ID: 37321155
[TBL] [Abstract][Full Text] [Related]
31. Molecular characterization in the prediction of disease extent in endometrial carcinoma.
Kolehmainen AM; Pasanen AM; Koivisto-Korander RL; Bützow RC; Loukovaara MJ
Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():478-483. PubMed ID: 33189427
[TBL] [Abstract][Full Text] [Related]
32. Prospective molecular classification of endometrial carcinomas: institutional implementation, practice, and clinical experience.
Devereaux KA; Weiel JJ; Pors J; Steiner DF; Ho C; Charu V; Suarez CJ; Renz M; Diver E; Karam A; Litkouhi B; Dorigo O; Kidd EA; Yang EJ; Folkins AK; Longacre TA; Howitt BE
Mod Pathol; 2022 May; 35(5):688-696. PubMed ID: 34743187
[TBL] [Abstract][Full Text] [Related]
33. Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer.
Raffone A; Travaglino A; Gabrielli O; Micheli M; Zuccalà V; Bitonti G; Camastra C; Gargiulo V; Insabato L; Zullo F
Arch Gynecol Obstet; 2021 Jun; 303(6):1393-1400. PubMed ID: 33754186
[TBL] [Abstract][Full Text] [Related]
34. Differential impact of clinicopathological risk factors within the 2 largest ProMisE molecular subgroups of endometrial carcinoma.
Pasanen A; Loukovaara M; Ahvenainen T; Vahteristo P; Bützow R
PLoS One; 2021; 16(9):e0253472. PubMed ID: 34473724
[TBL] [Abstract][Full Text] [Related]
35. Nuclear β-Catenin Expression in the Context of Abnormal p53 Expression Indicates a Nonserous Histotype in Endometrial Carcinoma.
Keyhanian K; Yang EJ; Howitt BE
Int J Gynecol Pathol; 2023 Sep; 42(5):435-442. PubMed ID: 36731035
[TBL] [Abstract][Full Text] [Related]
36. Characteristics and outcomes of surgically staged multiple classifier endometrial cancer.
Bogani G; Betella I; Multinu F; Casarin J; GhezzI F; Sorbi F; VizziellI G; Petrillo M; Cianci S; Berretta R; PaolinI B; FanfanI F; De Vitis L; Scambia G; Mariani A; Colombo N; Raspagliesi F
Eur J Surg Oncol; 2024 Jan; 50(1):107269. PubMed ID: 37984242
[TBL] [Abstract][Full Text] [Related]
37. Immunological profiling of molecularly classified high-risk endometrial cancers identifies
Eggink FA; Van Gool IC; Leary A; Pollock PM; Crosbie EJ; Mileshkin L; Jordanova ES; Adam J; Freeman-Mills L; Church DN; Creutzberg CL; De Bruyn M; Nijman HW; Bosse T
Oncoimmunology; 2017; 6(2):e1264565. PubMed ID: 28344870
[TBL] [Abstract][Full Text] [Related]
38. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.
Stelloo E; Nout RA; Osse EM; Jürgenliemk-Schulz IJ; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Nijman HW; Putter H; Bosse T; Creutzberg CL; Smit VT
Clin Cancer Res; 2016 Aug; 22(16):4215-24. PubMed ID: 27006490
[TBL] [Abstract][Full Text] [Related]
39. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment.
Leon-Castillo A; Horeweg N; Peters EEM; Rutten T; Ter Haar N; Smit VTHBM; Kroon CD; Boennelycke M; Hogdall E; Hogdall C; Nout RRA; Creutzberg CL; Ortoft G; Bosse T
Gynecol Oncol; 2022 Mar; 164(3):577-586. PubMed ID: 35078648
[TBL] [Abstract][Full Text] [Related]
40. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.
Stelloo E; Bosse T; Nout RA; MacKay HJ; Church DN; Nijman HW; Leary A; Edmondson RJ; Powell ME; Crosbie EJ; Kitchener HC; Mileshkin L; Pollock PM; Smit VT; Creutzberg CL
Mod Pathol; 2015 Jun; 28(6):836-44. PubMed ID: 25720322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
